| 发明名称 | Metabolite biomarkers for diagnosis and prognosis of pediatric septic shock | ||
| 摘要 | The present invention provides methods for differentiating a pediatric subject with pediatric septic shock from a healthy pediatric subject or one having sudden inflammatory response syndrome (SIRS). Also provided is a method of predicting pediatric septic shock mortality in a pediatric septic shock patient. | ||
| 申请公布号 | US8969017(B2) | 申请公布日期 | 2015.03.03 |
| 申请号 | US201414160712 | 申请日期 | 2014.01.22 |
| 申请人 | UTI Limited Partnership;Children's Hospital Medical Center | 发明人 | Mickiewicz Beata;Vogel Hans J.;Wong Hector R.;Winston Brent W. |
| 分类号 | G01N33/53;G01N31/00;G01R33/465 | 主分类号 | G01N33/53 |
| 代理机构 | Parker Highlander PLLC | 代理人 | Parker Highlander PLLC |
| 主权项 | 1. A method of differentiating a pediatric subject with pediatric septic shock from a healthy pediatric subject comprising: (a) obtaining a serum sample from said subject; (b) subjecting said sample to nuclear magnetic resonance (NMR) analysis of 2-hydroxybutyrate, 2-hydroxyisovalerate and lactate levels; and (c) diagnosing said subject as having pediatric shock when 2-hydroxybutyrate, 2-hydroxyisovalerate and lactate levels in said subject are elevated as compared to levels in a healthy pediatric subject. | ||
| 地址 | Calgary, Alberta CA | ||